Developing a risk mitigation plan for gene therapy manufacturing

Cell & Gene Therapy Insights 2020; 6(10), 1431–1443

10.18609/cgti.2020.156

Published: 9 November 2020
Interview
Claire Davies, John Moscariello, Michael Brewer, Christine Le Bec

John Moscariello

Senior Director, Viral Vector & Gene Editing Process Development, Bristol-Myers Squib 

Claire Davies

Head of Bioanalytics, Sanofi

Michael Brewer

Director, Global Principal Consultant, Regulatory, BioProduction, Thermo Fisher Scientific

Christine Le Bec

Head of CMC Gene Therapy, Sensorion Pharma